With the broader IPO calendar still muted, biopharma and life sciences issuers are cautiously testing the waters — and early trading in one name is giving the sector a modest tailwind. So far, just six companies have gone public in January, with four more slated to issue their shares this ... With the broader IPO calendar still muted, biopharma and life sciences issuers are cautiously testing the waters — and early trading in one name is giving the sector a modest tailwind. So far, just six companies have gone public in January, with four more slated to issue their shares this week, according to Renaissance Capital. III closed an IPO of 17.25 million shares, which includes 2.25 million shares issued after underwriters exercised their overallotment option at the usual blank-check IPO price of $10 per share. Total gross proceeds were $172.5 million. This special purpose acquisition company is sponsored by Cormorant Asset Management, which initially aimed to raise $125 million. This is Cormorant’s third SPAC. Helix III will focus on the same sectors as the two others: “We believe the biotechnology, medical technology, and life sciences sectors (including, for example, therapeutics, diagnostics, and medical devices) represent an enormous and growing target market with a large number of potential target acquisition opportunities,” the blank-check company’s regulatory filing says. Another prospective issuer, SpyGlass Pharma, recently filed initial plans to go public. The company, which is developing treatments for chronic eye diseases, has not yet disclosed the number of shares or the price target for the offering. A slow January IPO market has leaned on biopharma and life‑sciences issuers — several backed by hedge fund specialists — for the few deals getting done.

Original title: “With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma | Institutional Investor”

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

Original title: “The biopharma industry outlook on 2026: Optimism and tension”

After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? 1. Public smid-cap biotech stocks soared in the 2nd half of 2025;2. Historical data shows that when public smid-cap biotech stocks soar, the ... After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? 1. Public smid-cap biotech stocks soared in the 2nd half of 2025;2. Historical data shows that when public smid-cap biotech stocks soar, the biotech IPO market opens up the following year;3. Once the biotech IPO market opens, private funding should follow in subsequent quarters1. TABLE 1. Public smid-cap biotech returns and biotech IPOs 2015-2025 We analyzed historical data to confirm that when smid-cap biotech stocks soar, the biotech IPO market opens the following year. Biotech IPO activity does not respond immediately to changes in public biotech market performance. When IPO counts are compared with same-year XBI returns, the relationship is weak (See Table 1 and Fig 2 below. Same-year Pearson correlation (2015–2025): ~-0.07). This helps explain why IPO activity often remains subdued even after public biotech indices begin to rise. This lag likely reflects IPO preparation, investor marketing, and pricing dynamics. Thus, an increase in IPO filings Issuance responds to validated market strength, not contemporaneous conditions, and typically unfolds over subsequent quarters after the public biotech market indices and ETFs (e.g., XBI and IBB) rise, rather than immediately.

Original title: “Why 2026 Could Be a Breakout Year for Private Biotech Funding”

Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York Stock Exchange. The IPO for Veradermics will primarily be used to advance its hair loss pill VDPHL01 through drug approval and initial commercialization, the Connecticut-based biotech wrote in its prospectus. Specifically, Veradermics anticipates that its IPO raise will help support doctor education and brand awareness activities. Veradermics will also use the IPO money to beef up its supply chain and commercial infrastructure for the drug. In October last year, Veradermics brought in $150 million in series C funding, which it likewise funneled into VDPHL01. Just over two weeks after announcing their bids to go public, cancer outfit Eikon Therapeutics and hair growth biotech Veradermics have announced their fundraising targets. Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens · Following in the footsteps of Aktis Oncology last week, two more biotechs are looking to become publicly traded companies—an encouraging signal that the industry could be picking back up after last year’s drought. On Friday, hair growth biotech Veradermics and cancer-forward Eikon Therapeutics announced their bids to debut on the New York Stock Exchange and Nasdaq Global Market, respectively. Neither company has so far specified how much they plan to raise or when they expect to close their initial public offering (IPO).

Original title: “Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market - BioSpace”

SpyGlass Pharma, a Phase 3 biotech developing implants to treat chronic eye conditions, announced terms for its IPO on Thursday.The Aliso Viejo, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. - Renaissance Capital SpyGlass Pharma, a Phase 3 biotech developing implants to treat chronic eye conditions, announced terms for its IPO on Thursday. The Aliso Viejo, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the midpoint of the proposed range, SpyGlass Pharma would command a fully diluted market value of $549 million. SpyGlass Pharma is a late-stage biopharmaceutical company focused on chronic eye conditions by developing durable drug delivery solutions that provide long-term disease control and vision preservation.

Original title: “SGP IPO News - Chronic eye condition biotech SpyGlass Pharma sets terms for $150 million IPO”

AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn's and other fibrotic diseases, announced terms for its IPO on Thursday.The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to $17. AgomAb Therapeutics, a Belgian Phase 2 biotech developing TGFβ inhibitors for Crohn's and other fibrotic diseases, announced terms for its IPO on Thursday. The Antwerp, Belgium-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to $17. AgomAb also has a preclinical candidate, a HGF-mimetic monoclonal antibody targeting liver cirrhosis; the company concluded IND-enabling studies but is assessing further development and strategic options. AgomAb Therapeutics was founded in 2017 and plans to list on the Nasdaq under the symbol AGMB. J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are the joint bookrunners on the deal. The company is expected to price its IPO in February.

Original title: “AGMB IPO News - Belgian fibrotic disease biotech AgomAb Therapeutics sets terms for $200 million US IPO”

Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. | Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. hasn’t produced any new publicly listed drug developers of ... Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. | Despite remaining a fertile hunting ground for Big Pharmas to snap up biotechs or license new therapies, the U.K. hasn’t produced any new publicly listed drug developers of its own for many years. Could this be the year U.K.-based biotechs rediscover the allure of the public markets? Meanwhile, a concerted government attempt to get British pension funds to finally start investing in homegrown biotechs is beginning to pay off, according to Turner, who pointed to a well-known pension provider investing in VC firm Cambridge Innovation Capital last year. “Certainly, everyone's in a very positive mood because of the M&A, because of the IPO window potentially opening up, and some of those positive policy moves in the U.K. IPO biotech IPO UK mergers and acquisitions M&A Nasdaq Deals Biotech

Original title: “'Things are looking up': British biotechs consider going public after yearslong IPO drought”

After a blockbuster 2021, the IPO landscape within the biopharma sector reflects a cautious sentiment, especially amid various ongoing macroeconomic factors. 2025 has also seen a number of IPOs on Asian stock exchanges, outweighing those in the USA. With proceeds ranging from single-digit millions ... After a blockbuster 2021, the IPO landscape within the biopharma sector reflects a cautious sentiment, especially amid various ongoing macroeconomic factors. 2025 has also seen a number of IPOs on Asian stock exchanges, outweighing those in the USA. With proceeds ranging from single-digit millions to over a billion, learn how public offerings fared in this […] Avidity Biosciences completed the largest US biotech IPO, raising USD 690m. The company is developing antibody-oligonucleotide conjugates (AOCs), a novel modality designed to target previously undruggable diseases, with a particular focus on neuromuscular and rare genetic disorders. After a blockbuster 2021, the IPO landscape within the biopharma sector reflects a cautious sentiment, especially amid various ongoing macroeconomic factors. 2025 has also seen a number of IPOs on Asian stock exchanges, outweighing those in the USA. With proceeds ranging from single-digit millions to over a billion, learn how public offerings fared in this review, based on data from the Biotechgate database. Compared with the peak IPO years of the last half-decade, 2025 was defined less by scale and more by consistency. While large, headline-grabbing US biotech IPOs were scarce, a steady cadence of mid-sized offerings signaled renewed, if cautious, investor engagement with the sector.

Original title: “Biopharma IPOs: 2025 in Review - Biotechgate”

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced their IPOs this year. Meanwhile, Aktis Oncology began trading publicly earlier this month. Funds raised from the IPO will mainly help the biotech complete these Phase III trials and, if approved, support the initial launch of its bimatoprost candidate. Meanwhile, AgomAb’s most mature asset is AGMB-129, also known as ontunisertib, an orally available small-molecule blocker of the ALK5 protein, being studied for fibrostenosing Crohn’s disease. The 2026 IPO class welcomed two new members when California-based SpyGlass Pharma and New York’s AgomAb Therapeutics launched their respective bids last week to become publicly traded companies. Neither biotech has specified how much money it expects to make from its initial public offering. Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Two other biopharma companies have launched their IPOs so far this year, with hair growth specialist Veradermics and cancer-focused Eikon Therapeutics announcing their respective offerings earlier this month. Ahead of them, Aktis Oncology started trading publicly on Jan.

Original title: “2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut - BioSpace”

Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a renewed deal-making appetite and a lower interest rate scenario, even as they come to terms ‌with the political and regulatory environment. Jan 14 (Reuters) - Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a renewed deal-making appetite and a lower interest rate scenario, even as they come to terms ‌with the political and regulatory environment. Amid President Donald Trump's policy shifts, the most disruptive scenarios for healthcare now appear less likely, helping restore a degree of confidence after tariff threats, funding cuts and sweeping changes to the U.S. At least four industry experts said investors will seek out biotechs which have drugs in mid-to-late-stage development. "Once you've already developed some proof of concept and help reduce some of the early risk, that's where I think most investors continue to be interested," said Eisele. Companies with drugs in areas such as cancer, obesity, ‍precision medicine and respiratory diseases will be in focus, experts added. "I don't think we're going to get to an IPO-for-all market like we were in 2020 or 2021, but I think we will have a much more robust market than we've had over the past couple of years," said Seth Rubin, head of global equity capital markets at Stifel. The total U.S. biotech ⁠IPO proceeds in 2025 were $1.6 billion, paling ⁠in comparison to $16 billion raised ​in 2021, according to Dealogic data. Biotech stocks are regaining favor among investors, with many expecting 2026 ‍to be a potential turning point, driven by improving market dynamics, more mature trial data and a backlog of companies that delayed going public last year, according to Wall ‌Street analysts ‌and investors.

Original title: “US biotech sector poised for 2026 rebound as IPO interest revives | Reuters”

Aktis Oncology exceeded its own expectation | Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year. The company, which has accrued an impressive list of Big Pharma backers in its previous funding rounds, estimated earlier this week that it would sell 11.8 million shares priced between $16 and $18 apiece. But the IPO this morning sees the biotech reach the top end of the price range while bumping up the number of shares to 17.6 million. The $318 million proceeds make the biotech a larger IPO than any of the handful of biotech offerings last year—beating obesity biotech Metsera’s $275 million, LB Pharmaceuticals’ $285 million or MapLight Therapeutics’ $250 million IPOs. In its filing on Monday, Aktis explained how it had earmarked between $140 million and $150 million of the proceeds to fund the ongoing U.S. The biotech is hoping to carve out its own niche for Ac-AKY-1189 by using imaging radioisotopes conjugated to the drug to select patients most likely to benefit from the treatment. Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its second asset, Ac-AKY-2519, for B7-H3 expressing tumors, according to Monday’s filing. The company, which ended September with $246.2 million still in the bank, has previously said it expects the IPO proceeds will help keep the company financed until the first half of 2028. The biotech saw the likes of Bristol Myers Squibb and Merck & Co.’s MRL Ventures Fund join previous backer Eli Lilly for a $175 million series B last year.

Original title: “1st biotech IPO of 2026 sees Aktis bring in $318M via upsized offering”

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years. Prior to its IPO, Aktis banked $346 million in private funding to advance its pipeline of radiopharmaceuticals, including investments from MPM BioImpact, Vida Ventures and RA Capital. Last year was a slow one for biotech companies looking to raise money on the public markets, with less than a dozen firms pricing IPOs, according to BioPharma Dive data. Developing an Array of Diverse Vaccine Platforms Webinar - on demand • Provided by BioPharma Dive's studioID; Sponsored content by Novavax in partnership with studioID · Revolutionizing Next Generation Gene Therapies with On-Demand Large DNA Construct Synthesis and Novel, Designable Delivery Vehicles Webinar - on demand • Provided by Ansa Biotechnologies The latter, in particular, saw major success with its radiopharmaceuticals Pluvicto and Lutathera, setting off a chain of acquisitions by other pharmas looking for more precise medicines to attack tumors. Aktis’ IPO ranks as the sector’s third-largest since the start of 2024, only trailing offerings from Kyverna Therapeutics and CG Oncology. Radiopharmaceutical drug developer Aktis Oncology on Thursday said it raised $318 million from an initial public offering, the first for a biotechnology company in 2026.

Original title: “Aktis raises $318M in 2026’s first biotech IPO | BioPharma Dive”

Read our blog on healthcare IPOs of 2025 to explore how digital health and telehealth breakthroughs can transform the patient experience. This year’s innovations include Aptar Digital Health’s partnership with AstraZeneca to develop AI-powered screening algorithms for early detection of chronic kidney disease, an indication of how digital solutions are enhancing early intervention efforts. Amidst evolving venture funding and M&A activity, 2025’s initial public offerings (IPOs) highlight companies driving patient-centered, digitally-enabled healthcare solutions. Proceeds from the IPO are expected to support expansion of its affiliated practice network, new clinic openings in existing and nearby markets and continued investment in operational infrastructure. Wellgistics Health, based in Tampa, entered the market in February 2025. The company integrates digital health technology, pharmacy services and wholesale distribution, aiming to enhance patient outcomes. Wellgistics leverages strategic acquisitions, such as Wood Sage and Wellgistics LLC, along with collaborations with Tollo Health and Protega Pharmaceuticals, to streamline the pharmaceutical supply chain. With more than 20 years of expertise, Basel offers joint replacements, spine surgery, sports medicine and rehabilitation services. Its IPO will fuel regional expansion in Southeast Asia, support new technology investments and drive strategic acquisitions to broaden its footprint. Its services include womb-warming, agarwood moxibustion and Indonesian abdominal binding, along with various herbal supplements and skincare products. In fiscal 2025, the company reported $6.2 million in revenue and $1.2 million in net income, primarily from wellness services. The IPO proceeds will support research and development, expansion and strategic acquisitions.

Original title: “Healthcare IPOs of 2025: Emerging Companies to Watch - Xtalks”

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling strong investor demand for 2026's first U.S. listing. Wall Street is expecting biotech IPOs to rebound in 2026 after sweeping changes at the U.S. health regulator and funding cuts by the Trump administration hindered listings from the sector last year. Lilly's move builds on its partnership with Aktis, struck in 2024, to develop tumor-targeting radiopharmaceuticals. "Eli Lilly’s commitment ... shows that (Aktis') cancer-targeting technology has passed the scrutiny of a major industry leader," said IPOX research associate Lukas Muehlbauer. "This backing is particularly significant because Big Pharma has been actively buying innovation in the sector," Muehlbauer said, pointing to the acquisitions in 2023 of radiopharma startups RayzeBio and Point Biopharma shortly after their IPOs. Basil writes stories across the U.S. finance file including banks, asset managers, payment firms, insurers, and exchange operators. He also covers initial public offerings on U.S. exchanges and venture capital funding.

Original title: “Aktis Oncology secures Lilly as anchor investor for upsized US IPO | Reuters”

ACF, Office of Refugee Resettlement (ORR) announces the intent to award a single-source cooperative agreement in the amount of up to $1,000,000 to the Welcoming Initiative for Newcomers (WIN) in San Diego, CA to conduct a baseline assessment of state readiness and capacity to implement a state-centered refugee resettlement framework under the Program of Initial Resettlement. The purpose is to empower states with the tools and insights needed to take control of their refugee resettlement recommen

Original title: “Announcement of the Intent To Award a Sole-Source Cooperative Agreement to the Welcoming Initiative for Newcomers in San Diego, CA”

The Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to EnZeta Immunotherapies, Inc., a company located in Coral Gables, FL.

Original title: “Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $1,600,000 over a five-year period, in response to an unsolicited proposal that has been submitted by University of Southern Denmark (SDU). The award will support a comparable study of the optimal timing and delivery of monovalent Hepatitis B vaccinations on newborns in Guinea-Bissau. Activities will include conducting a randomized controlle

Original title: “Notice of Award of a Single Source Unsolicited Grant To Fund University of Southern Denmark (SDU)”

The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program.

Original title: “FDA Awards Second Batch of National Priority Vouchers”

Today, the Centers for Disease Control and Prevention (CDC) announced more than $176 million in funding to support 48 public health partners to strengthen the public health system in the United States.

Original title: “CDC Awards Over $176 Million to Strengthen U.S. Public Health Infrastructure and Workforce”

The Centers for Disease Control and Prevention (CDC) is awarding more than $28.6 million in additional funding to 44 states and the District of Columbia to support their responses to the opioid overdose epidemic.

Original title: “CDC awards $28.6 million to help states fight opioid overdose epidemic - Press Release”